Pyrukynd Tablet, Film Coated
Product Images NDC 71334-210

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Pyrukynd (NDC 71334-210). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Agios Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pyrukynd 01)

Chemical structure of mitapivat, the active ingredient in PYRUKYND. The image shows the molecular formula including piperazine rings, sulfonamide groups, and a sulfate trihydrate salt component, consistent with the drug's chemical composition.*

FDA Label Image

Figure 1 (Pyrukynd 02)

A waterfall plot showing the average change from baseline in hemoglobin (Hb) levels at weeks 16, 20, and 24 for PYRUKYND (mitapivat) and placebo groups, each with 40 subjects. The left panel displays individual Hb changes for PYRUKYND-treated patients, highlighting responders and non-responders with dose optimization symbols for 5 mg, 20 mg, and 50 mg twice daily. The right panel shows similar data for placebo patients, illustrating smaller Hb changes. Baseline Hb levels below 8.5 g/dL are marked.*

FDA Label Image

Figure 2 (Pyrukynd 03)

A line graph depicting the least squares mean change from baseline in hemoglobin levels (g/dL) over 24 weeks, comparing PYRUKYND and placebo groups (each N=40). The PYRUKYND group shows an increase peaking near week 16, while the placebo group remains around baseline. Error bars indicate 95% confidence intervals.*

FDA Label Image

Principal Display Panel (5 mg Tablet Blister Pack Carton)

Packaging label for PYRUKYND 5 mg tablets containing mitapivat, film-coated oral tablets. The label shows a 56 tablet package, a 4-week supply with blister packs, manufactured and distributed by Agios Pharmaceuticals, Inc. The label includes storage instructions, a barcode, and regulatory information.*

FDA Label Image

Principal Display Panel (20 mg Tablet Blister Pack Carton)

Packaging label for PYRUKYND (mitapivat) tablets, 20 mg per tablet, film-coated oral tablets. The label indicates a 56-tablet supply, manufactured and distributed by Agios Pharmaceuticals, Inc. It includes storage instructions, dosage form, and a barcode. The label also notes the product is Rx Only and features branding elements and a 2D code.*

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Pack Carton)

Packaging label for PYRUKYND 50 mg film-coated tablets (mitapivat) by Agios Pharmaceuticals, Inc. The label states each tablet contains 50 mg mitapivat. The package holds 56 tablets providing a 4-week supply, and includes storage instructions and a picture of an oblong blue tablet marked 'M50.' The label includes the NDC 71334-215-50 and safety information such as 'Do not use if seal is broken or damaged.'*

FDA Label Image

Principal Display Panel (5 mg Tablet Blister Pack Carton)

Packaging label for Pyrukynd (mitapivat) tablets 5 mg TAPER PACK. The label indicates the product is oral film-coated tablets, supplied in a pack of 7 tablets for a one-week taper regimen. The labeler is Agios Pharmaceuticals, Inc. and includes storage, dosage instructions, and manufacturing details. The design features purple and white colors with the Pyrukynd logo.*

FDA Label Image

Principal Display Panel (20 mg/5 mg Tablet Blister Pack Carton)

PYRUKYND (mitapivat) tablets 20 mg and 5 mg TAPER PACK carton for oral use. The package contains 14 film-coated tablets in two 7-day blister wallets with 7 tablets per wallet, featuring dosing instructions for Week 1 with 20 mg tablets and Week 2 with 5 mg tablets. Manufactured and distributed by Agios Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (50 mg/20 mg Tablet Blister Pack Carton)

Packaging label for PYRUKYND (mitapivat) tablets 50 mg and 20 mg TAPER PACK by Agios Pharmaceuticals, Inc. The label shows a 14-tablet carton containing film-coated oral tablets. It indicates dosing of 50 mg per tablet in week 1 and 20 mg per tablet in week 2. Storage information, manufacturer details, and a barcode are also included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.